Drug intelligence / Profile preview

5-phospho-D-arabinohydroxamic acid

Development stage: Unknown
Modality: Small Molecules

Overview

5-phospho-D-arabinohydroxamic acid is a synthetic small molecule belonging to the class of pentose phosphates. It is structurally similar to reaction intermediates in sugar metabolism and acts as a potent inhibitor of phosphoglucose isomerase by mimicking the cis-enediol(ate) intermediate but with a nitrogen atom replacing C1. This compound has been used experimentally to study enzyme mechanisms and inhibition but has no approved medical indications or clinical use[1][8].

Other names: 5-phospho-D-arabinohydroxamic acid(2R,3R,4S)-2,3,4-Trihydroxy-5-(hydroxyamino)-5-oxopentyl dihydrogen phosphate

Targets

GPI (Glucose-6-phosphate isomerase)PMI (Plasmepsin I)

Beyond the preview

Go deeper on 5-phospho-D-arabinohydroxamic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-phospho-D-arabinohydroxamic acid.

Explore the full profile